☰

Yao Liu

Affiliations: 
Dana-Farber Cancer Institute and Harvard Medical School, USA 
Area:
cancer research
Google:
"Yao Liu"
Mean distance: (not calculated yet)
 
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor
Nathanael Gray post-doc 2016- Dana-Farber Cancer Institute and Harvard Medical School

Children

Sign in to add trainee

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Chen M, Yin B, Liu Y, et al. (2024) ARRDC3 regulates the targeted therapy sensitivity of clear cell renal cell carcinoma by promoting AXL degradation. Cell Cycle (Georgetown, Tex.). 1-14
Song Y, Malpica L, Cai Q, et al. (2023) Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study. The Lancet. Oncology
Arwood ML, Liu Y, Harkins SK, et al. (2023) New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation. Cell Chemical Biology
Lu W, Liu Y, Gao Y, et al. (2023) Development of a Covalent Inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1. Journal of Medicinal Chemistry. 66: 3356-3371
Fan M, Lu W, Che J, et al. (2022) Covalent disruptor of YAP-TEAD association suppresses defective hippo signaling. Elife. 11
Zhang S, Peng X, Li X, et al. (2021) BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair. Cell Death & Disease. 12: 546
Jiang T, Wang G, Liu Y, et al. (2021) Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for fusion cancers. Acta Pharmaceutica Sinica. B. 11: 355-372
Liu Y, Hao M, Leggett A, et al. (2020) Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13. Journal of Medicinal Chemistry
Wang G, Zhao Y, Liu Y, et al. (2020) Discovery of a novel dual-target inhibitor of ERK1 and ERK5 that induces regulated cell death to overcome compensatory mechanism in specific tumor types. Journal of Medicinal Chemistry
Kurppa KJ, Liu Y, To C, et al. (2020) Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell. 37: 104-122.e12
See more...